

**Mangalam Drugs and Organics Limited**

Regd Office Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001  
 ☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

Report of the Committee of Independent Directors ("ID Committee" / "Committee") of Mangalam Drugs and Organics Limited on the Scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("MLPL" or "First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("SJPL" or "Second Transferor Company") with Mangalam Drugs and Organics Limited ("MDOL" or "Transferee Company").

This Report is considered and approved by the Committee in its meeting held on 18<sup>th</sup> June, 2024.

**Members present and participated:**

Mrs. Nidhi Shantanu Mundada : Chairperson of the Committee  
 Mr. Rukmesh Prabhukumar Dhandhanla : Member  
 Mr. Praveen Saxena : Member

**Convener:**

Mr. Jayant Barde : Company Secretary & Compliance Officer

**1. Background**

1.1 The Committee has considered the proposed Scheme of Merger by Absorption of First Transferor Company and Second Transferor Company with the Transferee Company and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 ("Act") (hereinafter referred to as the "Scheme" / "Merger").

The First Transferor Company is a wholly owned subsidiary of the Transferee Company and is not listed on any stock exchange in India or abroad.

1.2 The equity shares of the Transferee Company are listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE", and together with BSE, the "Stock Exchanges"). The Transferee Company will be filing the Scheme along with necessary documents with the Stock Exchanges for their no objection or observation letter pursuant to Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations") and applicable statutory provisions.

1.3 The Committee was briefed about the proposed Merger, valuation and share exchange ratio. The Committee reviewed followings

- a) Draft Scheme of Merger by Absorption;
- b) Valuation Report dated 18<sup>th</sup> June, 2024 Issued by Nitish Chaturvedi, Registered Valuer, Securities or Financial Assets ("Valuation Report");
- c) Fairness Opinion dated 18<sup>th</sup> June, 2024 Issued by EKADRISHT Capital Private Limited, SEBI Registered Category I Merchant Banker ("Fairness Opinion");

For Mangalam Drug & Organics Ltd.

*Jayant Barde*  
 Company Secretary



**CERTIFIED TRUE COPY**

# Mangalam Drugs and Organics Limited



Regd Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

- d) Financial statements of the First Transferor Company, Second Transferor Company and Transferee Company for the year ended March 31, 2022, March 31, 2023 and March 31, 2024;
  - e) Certificate dated 18<sup>th</sup> June, 2024 Issued by the Statutory Auditors of the Transferee Company, to the effect that the Scheme is in compliance with applicable Accounting Standards specified in Section 133 of the Act ("Statutory Auditors Certificate"); and
  - f) Other relevant documents relating to the Merger
- 1.4 The Committee reviewed the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 ("SEBI Circular"), relating to requirement of "Report from the Committee of Independent Directors recommending the draft Scheme, taking into consideration, *Inter alia*, that the scheme is not detrimental to the shareholders of the listed entity".

## 2. Proposed Scheme and review

### 2.1 The salient features of the Scheme are as under:

- a) Merger of the First Transferor Company and Second Transferor Company with the Transferee Company, transfer of Undertaking (as defined in the Scheme) of the First Transferor Company and Second Transferor Company into the Transferee Company, and issue of equity shares by Transferee Company to the shareholders of Second Transferor Company.
- b) Rationale and purpose of the Scheme are as described in detail in the Scheme.
- c) Upon the Scheme becoming effective and in consideration of the Merger, including the transfer and vesting of the Undertaking in the Transferee Company, the Transferee Company shall without any further application or deed, issue and allot equity shares of the Transferee Company at face value, credited as fully paid up, to the extent indicated below, to the Eligible Members or to such of their respective heirs, executors, administrators or other legal representatives or other successors in title as may be recognized by the Board of Directors of the Transferor Companies / the Transferee Company in the following manner (the "Share Exchange Ratio")

#### a) Between First Transferor Company and Transferee Company:

As the First Transferor Company is wholly-owned subsidiary of the Transferee Company, no consideration shall be payable pursuant to the Merger by Absorption of the First Transferor Company with the Transferee Company, and the equity shares held by the Transferee Company in the Transferor Company shall stand cancelled without any further act, application or deed.

#### b) Between Second Transferor Company and Transferee Company:

For Mangalam Drug & Organics Ltd.

*Jayant Bardi*  
Company Secretary



**CERTIFIED TRUE COPY**

# Mangalam Drugs and Organics Limited



Regd Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

The Transferee Company shall without any further act or deed, issue and allot 265 Equity Shares of Rs. 10/- each to the Eligible Members of Second Transferor Company for every 1 (One) Equity Share of Face Value of Rs. 10/- each held by Eligible Members of Second Transferor Company.

The equity shares of the Transferor Company shall be cancelled and extinguished.

- 2.2 Pursuant to the Scheme, the Transferee Company shall account for the Merger as per the applicable accounting principles prescribed under Indian Accounting Standards (IndAS).
  - 2.3 Further, the Fairness Opinion confirmed that the Share Exchange Ratio as mentioned in the Valuation Report is fair to the Transferee Company, and their respective shareholders.
  - 2.4 The Scheme is proposed to be effective from the Appointed Date (as defined in the Scheme) and operative from the Effective Date (as defined in the Scheme).
  - 2.5 The equity shares of the Transferee Company to be issued to the shareholders of the Second Transferor Company (except to the Transferee Company itself) pursuant to the Scheme shall be listed on the Stock Exchanges.
3. **Scheme not Detrimental to the Shareholders of the Transferee Company**

The consolidation of Transferor Companies with the Transferee Company will be in the interest of stakeholders of Transferor Companies and Transferee Company to have an increased capability for running this business and pursue growth opportunities.

The Scheme will result in economies of scale and consolidation of opportunities will contribute to make the Transferee Company more profitable and accordingly further enhance the overall shareholder value. Further, the scheme will not in any manner adversely affect the rights / interest of shareholders of First Transferor Company, Second Transferor Company and Transferee Company

The Committee members also discussed and deliberated upon the rationale and salient features of the Scheme. In light of the same and the fair Share Exchange Ratio, Valuation Report, Fairness Opinion and other documents presented before the Committee, the Committee is of the informed opinion that the proposed Scheme is in the best interest of the shareholders of the Transferee Company.

4. **Recommendations of the Committee**

The Committee considered the Scheme and after due deliberations and discussion on relevant provisions of the Scheme, Share Exchange Ratio, Valuation Report, Fairness Opinion, Statutory Auditors Certificate, recommends the draft Scheme for favorable consideration to the Board of

**CERTIFIED TRUE COPY**

For Mangalam Drug & Organics Ltd.

*Jayant Bhardwaj*  
Company Secretary



# Mangalam Drugs and Organics Limited



Regd Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

Directors of Transferee Company, the Stock Exchanges and Securities Exchange Board of India and other appropriate authorities.

This Report of the Committee of Independent Directors is made after considering the necessary documents and the same shall be treated as compliance under the applicable provisions of the SEBI Listing Regulations, SEBI Circular and other applicable provisions, if any. The Committee is entitled to make relevant modifications to this Report, if required, and such modifications or amendments shall be deemed to form part of this Report.

For Committee of Independent Directors of  
Mangalam Drugs and Organics Limited



Mrs. Nidhi Shantanu Mundada  
Chairperson  
DIN : 08134952  
Date : 18.06.2024

For Mangalam Drug & Organics Ltd.

  
Company Secretary

**CERTIFIED TRUE COPY**